* need for oro-tracheal intubation and/or invasive mechanical ventilation at the start of the study. * ast/alt with values greater than 5 times normal levels. * neutrophils \< 1.500 cell/mmc. * platelets \< 50.000 cell/mmc. * sepsis or pneumonia documented by other pathogens than sars-cov-2. * existence of any life-threatening comorbidity or any other medical condition that, in the investigator's opinion, makes the patient unsuitable for inclusion. * inability to obtain informed consent. * positivity for hbv, hcv or tuberculin test serology. * pregnancy. * use of other previous or concomitant biological treatments. patients in concomitant treatment with other biologicals that may interfere will be excluded: tocilizumab, canakinumab, tnfalfa inhibitors, jakiinibs * severe renal dysfunction (estimated glomerular filtration rate ≤ 30 ml / min / 1.73 m2) or receive continuous renal replacement therapy, hemodialysis or peritoneal dialysis. * uncontrolled hypertension (sitting systolic blood pressure \> 180 mmhg or diastolic blood pressure \> 110 mmhg). * administration of plasma from convalescent patients who have recovered from sars-cov-2 infection. * history of hypersensitivity or allergy to any component of the study drug. * enrollment in another concurrent intervention clinical trial, or intake of an investigational medication within three months or 5 half-lives prior to inclusion in this study, if deemed to interfere with the objectives of this study as assessed by the investigator. * predictable inability to cooperate with given instructions or study procedures.

* need for oro-tracheal intubation and/or invasive mechanical ventilation at the start of the study. * ast/alt with values greater than 5 times normal levels. * neutrophils \< 1.500 cell/mmc. * platelets \< 50.000 cell/mmc. * sepsis or pneumonia documented by other pathogens than sars-cov-2. * existence of any life-threatening comorbidity or any other medical condition that, in the investigator's opinion, makes the patient unsuitable for inclusion. * inability to obtain informed consent. * positivity for hbv, hcv or tuberculin test serology. * pregnancy. * use of other previous or concomitant biological treatments. patients in concomitant treatment with other biologicals that may interfere will be excluded: tocilizumab, canakinumab, tnfalfa inhibitors, jakiinibs * severe renal dysfunction (estimated glomerular filtration rate ≤ 30 ml / min / 1.73 m2) or receive continuous renal replacement therapy, hemodialysis or peritoneal dialysis. * uncontrolled hypertension (sitting systolic blood pressure \> 180 mmhg or diastolic blood pressure \> 110 mmhg). * administration of plasma from convalescent patients who have recovered from sars-cov-2 infection. * history of hypersensitivity or allergy to any component of the study drug. * enrollment in another concurrent intervention clinical trial, or intake of an investigational medication within three months or 5 half-lives prior to inclusion in this study, if deemed to interfere with the objectives of this study as assessed by the investigator. * predictable inability to cooperate with given instructions or study procedures.

- need for oro-tracheal intubation and/or invasive mechanical ventilation at the start of the study. - ast/alt with values greater than 5 times normal levels. - neutrophils < 1.500 cell/mmc. - platelets < 50.000 cell/mmc. - sepsis or pneumonia documented by other pathogens than sars-cov-2. - existence of any life-threatening comorbidity or any other medical condition that, in the investigator's opinion, makes the patient unsuitable for inclusion. - inability to obtain informed consent. - positivity for hbv, hcv or tuberculin test serology. - pregnancy. - use of other previous or concomitant biological treatments. patients in concomitant treatment with other biologicals that may interfere will be excluded: tocilizumab, canakinumab, tnfalfa inhibitors, jakiinibs - severe renal dysfunction (estimated glomerular filtration rate ≤ 30 ml / min / 1.73 m2) or receive continuous renal replacement therapy, hemodialysis or peritoneal dialysis. - uncontrolled hypertension (sitting systolic blood pressure > 180 mmhg or diastolic blood pressure > 110 mmhg). - administration of plasma from convalescent patients who have recovered from sars-cov-2 infection. - history of hypersensitivity or allergy to any component of the study drug. - enrollment in another concurrent intervention clinical trial, or intake of an investigational medication within three months or 5 half-lives prior to inclusion in this study, if deemed to interfere with the objectives of this study as assessed by the investigator. - predictable inability to cooperate with given instructions or study procedures.

- need for oro-tracheal intubation and/or invasive mechanical ventilation at the start of the study. - ast/alt with values greater than 5 times normal levels. - neutrophils < 1.500 cell/mmc. - platelets < 50.000 cell/mmc. - sepsis or pneumonia documented by other pathogens than sars-cov-2. - existence of any life-threatening comorbidity or any other medical condition that, in the investigator's opinion, makes the patient unsuitable for inclusion. - inability to obtain informed consent. - positivity for hbv, hcv or tuberculin test serology. - pregnancy. - use of other previous or concomitant biological treatments. patients in concomitant treatment with other biologicals that may interfere will be excluded: tocilizumab, canakinumab, tnfalfa inhibitors, jakiinibs - severe renal dysfunction (estimated glomerular filtration rate ≤ 30 ml / min / 1.73 m2) or receive continuous renal replacement therapy, hemodialysis or peritoneal dialysis. - uncontrolled hypertension (sitting systolic blood pressure > 180 mmhg or diastolic blood pressure > 110 mmhg). - administration of plasma from convalescent patients who have recovered from sars-cov-2 infection. - history of hypersensitivity or allergy to any component of the study drug. - enrollment in another concurrent intervention clinical trial, or intake of an investigational medication within three months or 5 half-lives prior to inclusion in this study, if deemed to interfere with the objectives of this study as assessed by the investigator. - predictable inability to cooperate with given instructions or study procedures.